AstraZeneca/Actavis Antibiotic Faces Limited Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA allowed flexibility in AstraZeneca/Actavis’ gram-negative antibiotic development program, but agency’s advisory committee briefing documents propose more restrictive label than companies are seeking.
You may also be interested in...
FDA Worries About Off-Label Use, Stewardship With Limited-Population Approval Pathway
FDA asks groups how it can help ensure prescribing is limited for products approved under proposed new pathway, but several say, other than labeling, it may be out of the agency’s hands.
Califf Clears First Senate Hurdle, But FDA Decision On Abortion Pill May Complicate Final Confirmation
Republican opposition to Califf over agency’s recent move to relax its Mifeprex restrictions is ominous since, in order be confirmed as commissioner, he’ll need enough GOP votes to make up for Democratic opposition over his opioid track record and connections to pharma industry.
Califf Clears First Senate Hurdle, But FDA Abortion Pill Decision May Complicate Final Confirmation
Republican opposition to Califf over the agency’s recent move to relax its Mifeprex restrictions is ominous since in order be confirmed as FDA commissioner he’ll need enough GOP votes to make up for Democratic opposition over his opioid track record and connections to the drug industry.